Fresh analysis reveals that individuals who come off popular weight-loss injections like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle plans.
Published data in a major medical journal shows that while overweight individuals frequently drop about a fifth of their body weight while on the medication, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Users buying these treatments should be informed of the risk of quick rebound weight gain when the treatment ends," cautioned expert Dr. Susan Jebb.
This pace of recovery implies a reversion to original mass in about a year and a half.
Analyzing Approaches
The research, which looked at dozens of trials involving thousands of participants, compared the effects of these new drugs with conventional dieting.
Researchers emphasize that people who lose weight through lifestyle changes alone generally have a more gradual creep back—perhaps 0.1 kg a month—after stopping.
Explaining the Quick Rebound
Experts suggest the way of the drugs is key to understanding the accelerated regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 levels far above than the body's typical production could lead to the body to produce less of its endogenous hormone, and could reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement results in hunger is uncontrolled, making binge eating much more probable."
An Ongoing Issue?
The NHS advise the injections for people with weight-linked health risks, alongside prescribed lifestyle changes.
A number of clinicians say that, considering the high risk of relapse, the therapy might need to be ongoing.
This view is supported by drug manufacturers, who say that the results "highlight the persistent character of obesity," similar to managing conditions like diabetes.
User Accounts
People who have discontinued the medication report a intense resurgence of appetite.
"I experienced something that goes on and you become ravenous," said one woman.
The struggle is worsened if users have not developed sustainable lifestyle or habit modifications during therapy.
Significant Interest
Survey data indicate that a significant number of adults in the UK have used weight-loss jabs in the past year, with desire continuing to grow.
- Adoption is greater among females compared to males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Finally, experts caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic fix and lasting health benefits hinges on combined behavioural support.
